The increasing field of immuno-oncology is directed on utilizing the immune system's own defenses against malignancies. Among these methods, inhibiting MAGEA3 with targeted antibodies holds great hope. MAGEA3, a part of the melanoma-associated antigen family, is often overexpressed in a variety o